1. Home
  2. AVNT vs EWTX Comparison

AVNT vs EWTX Comparison

Compare AVNT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avient Corporation

AVNT

Avient Corporation

HOLD

Current Price

$36.30

Market Cap

3.4B

Sector

Industrials

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$31.50

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVNT
EWTX
Founded
1927
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.3B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
AVNT
EWTX
Price
$36.30
$31.50
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$41.50
$37.38
AVG Volume (30 Days)
691.7K
741.7K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
3.10%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
$3,835,500,000.00
N/A
Revenue This Year
$4.84
N/A
Revenue Next Year
$3.39
N/A
P/E Ratio
$39.99
N/A
Revenue Growth
1.71
N/A
52 Week Low
$27.48
$10.60
52 Week High
$44.85
$32.80

Technical Indicators

Market Signals
Indicator
AVNT
EWTX
Relative Strength Index (RSI) 51.45 58.39
Support Level $35.07 $28.72
Resistance Level $38.15 N/A
Average True Range (ATR) 1.07 1.46
MACD 0.32 0.11
Stochastic Oscillator 92.35 73.03

Price Performance

Historical Comparison
AVNT
EWTX

About AVNT Avient Corporation

Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: